Approval · Notice of Compliance 809 · 2001
TRIZIVIR: Notice of Compliance 809
Issued October 17, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 809
- Date
- October 17, 2001
- Company
- Glaxo Wellcome Biochem Inc.
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Therapeutic class
- Antiretroviral agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TRIZIVIR | 02244757 | Cancelled Post Market |
Medicinal ingredients
- ZIDOVUDINE 300 MG per TAB
- LAMIVUDINE 150 MG per TAB
- ABACAVIR SULFATE 300 MG per TAB